Receptor pharmacology
GLP-1 vs GIP vs glucagon receptor agonism
Receptor-level comparison of GLP-1, GIP and glucagon receptor agonism, dual and triple agonist combinations, and why receptor pharmacology does not automatically translate into outcome benefit.
This page explains receptor-level differences between GLP-1, GIP and glucagon agonism and how dual- and triple-receptor combinations translate into the mechanisms studied in clinical trials. GLP-1 receptor agonism drives the licensed incretin class; adding GIP agonism (tirzepatide) produces larger observed weight reductions in studied populations; adding glucagon agonism (retatrutide) is under investigation. Receptor pharmacology does not automatically predict outcome-trial benefit. Cross-trial comparison has limits — see the linked research-methods primer.
GLP-1 receptor agonism
Activation of the GLP-1 receptor — in pancreatic β-cells, hypothalamic and brainstem appetite circuits, vagal afferents, the stomach and the vasculature — drives the integrated effects of semaglutide, liraglutide and dulaglutide. See the GLP-1 receptor signalling mechanism page for detail.
GIP receptor agonism (in combination)
GIP receptor agonism, added to GLP-1 receptor agonism, produces larger trial-measured weight reductions in studied populations (tirzepatide). The relative contribution of GIP versus GLP-1 to the integrated effect remains an active research question; see the GIP receptor signalling mechanism page.
Glucagon receptor agonism (in combinations)
Carefully balanced glucagon receptor agonism alongside potent GLP-1 (and sometimes GIP) agonism contributes to energy expenditure and hepatic fat oxidation in the dual and triple agonist class. The integrated pharmacology of retatrutide, survodutide, pemvidutide, mazdutide and cotadutide is built around this logic. See glucagon receptor agonism.
What receptor pharmacology does not predict
- Receptor selectivity in vitro does not predict integrated clinical outcomes.
- Phase 2 magnitude in a single trial does not predict phase 3 confirmation.
- Greater weight reduction in obesity does not automatically translate to greater cardiovascular, kidney or hepatic outcome benefit.
- Mechanistic plausibility is necessary but not sufficient for regulatory approval.
Why this matters for cross-class comparison
Quoting a triple-agonist phase 2 number next to a GLP-1 mono-agonist outcome trial as if both are equivalent evidence misrepresents the underlying state of the literature. The right comparison is at the same evidence stage and ideally head-to-head; see how to compare trials without overclaiming.
- Trial data does not prove suitability for any individual.
- Preclinical data does not establish human safety or efficacy.
- Phase 2 data is not the same as regulatory approval.
- Weight-change outcomes do not automatically prove cardiovascular benefit.
- Short-duration trials cannot fully establish long-term safety.
- Research-only compounds should not be used outside authorised research.
Related mechanisms
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for prescription medicine classification
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency — EPARs
EPARs and product information for approved GLP-1/GIP medicines
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial comparison of GLP-1 class medicines on this site